Clinical Trials Sponsored by MingSight Pharmaceuticals, Inc

Total 4971 results

MingSight Pharmaceuticals, Inc

Recruiting

A Study Of The Selective PKC-β Inhibitor MS- 553

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Aggressive Lymphoma

United States
MingSight Pharmaceuticals, Inc
Shenzhen MingSight Relin Pharmaceutical Co., Ltd

Recruiting

A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Relapsed or Refractory B-cell Lymphoma | Marginal Zone Lymphoma (MZL)

China
MingSight Pharmaceuticals Pty Limited

Completed

A Multiple-Ascending Dose Study of MS-553 in Healthy Volunteers

Safety and PK in Healthy Volunteers

Australia
Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.

Recruiting

A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL

Small Lymphocytic Lymphoma | Lymphocytic Leukemia

China
Molecular Insight Pharmaceuticals, Inc.

Approved for marketing

Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Pheochromocytoma | Paraganglioma

United States
Molecular Insight Pharmaceuticals, Inc.

Completed

Safety and Efficacy Iodofiltic Acid I 123 in the Treatment of Acute Coronary Syndrome (Zeus-ACS)

Acute Coronary Syndrome

United States, Canada
Molecular Insight Pharmaceuticals, Inc.

Withdrawn

Study to Evaluate the Efficacy and Safety of 90Y-SMT487 in Subjects With Symptomatic Malignant Carcinoid Tumors

Malignant Carcinoid Tumor
Molecular Insight Pharmaceuticals, Inc.

Completed

Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging in Men With Prostate Cancer Undergoing Prostatectomy and/or Pelvic Lymph Node Dissection

Prostate Cancer

United States
Molecular Insight Pharmaceuticals, Inc.

Completed

99mTc-MIP-1404 for Imaging Prostate Cancer: Phase I Clinical Study to Assess the Image Quality of a Simplified Kit Formulation Compared to a Multi-step Preparation of 99mTc-MIP-1404

Prostate Cancer

United States
Molecular Insight Pharmaceuticals, Inc.

Completed

Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of Two Prostate Cancer Imaging Agents

Prostate Cancer

United States
Molecular Insight Pharmaceuticals, Inc.

Terminated

Phase I Safety and Dosimetry Study in Patients With Confirmed Metastatic Melanoma

Metastatic Melanoma

United States
Molecular Insight Pharmaceuticals, Inc.

Unknown

A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Pheochromocytoma | Paraganglioma

United States
Molecular Insight Pharmaceuticals, Inc.

Completed

A Study of 99mTc-MIP-1404 and 99mTc-MIP-1405 in Patients With Metastatic Prostate Adenocarcinoma and Healthy Volunteers

Prostate Cancer

United States
Molecular Insight Pharmaceuticals, Inc.

Completed

ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid

Pheochromocytoma | Paraganglioma | Carcinoid
Molecular Insight Pharmaceuticals, Inc.

Completed

Study to Evaluate 99mTc-MIP-1404 SPECT/CT Imaging in Men With Biopsy Proven Low-Grade Prostate Cancer (proSPECT-AS)

Prostate Cancer

United States, Canada
Molecular Insight Pharmaceuticals, Inc.

Completed

N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma

Neuroblastoma

United States
Molecular Insight Pharmaceuticals, Inc.

Completed

A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology

Prostate Cancer

United States, Belgium, Italy, Czech Republic, Hungary, Netherlands, Poland, Russian Federation
Molecular Insight Pharmaceuticals, Inc.

Completed

Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

Pheochromocytoma | Paraganglioma

United States
Molecular Insight Pharmaceuticals, Inc.

Withdrawn

Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma

Neuroblastoma

United States, Canada
Molecular Insight Pharmaceuticals, Inc.

Completed

A Phase 1 Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging to Histology in Men With Prostate Cancer

Prostate Cancer

United States
Molecular Insight Pharmaceuticals, Inc.

Terminated

Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and Paraganglioma

Pheochromocytoma | Paraganglioma

United States
Molecular Insight Pharmaceuticals, Inc.

Completed

A Phase I Pilot Study Comparing 123I MIP 1072 Versus 111In Capromab Pendetide in Subjects With Metastatic Prostate Cancer

Prostate Cancer

United States
Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.
Fountain Medical Development Co., Ltd.

Recruiting

MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema

Diabetic Retinopathy | Diabetic Macular Edema | Macular Edema | Type 2 Diabetes With Diabetic Macular Edema | Type 1 Diabetes With Diabetic Macular Edema

China
University of Iowa
Molecular Insight Pharmaceuticals, Inc.

Withdrawn

90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)

Neuroendocrine Tumor | Neuroblastoma

United States
Molecular Insight Pharmaceuticals, Inc.
National Cancer Institute (NCI)

Withdrawn

A Pilot Study of 123I-MIP-1072 SPECT/CT Imaging With Optional Compact Gamma Camera Probe Imaging in Men With Prostate Cancer Undergoing Prostatectomy

Prostate Cancer

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment

Chronic HBV Infection

Hong Kong, Taiwan
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects

RSV Infection

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2)

Chronic HBV Infection

United States, Canada
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP-938 in Healthy Subjects

RSV Infection

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD

Presumptive NAFLD

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects

RSV Infection

United States
Alexza Pharmaceuticals, Inc.
Pharmaceutical Research Associates

Unknown

Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder

Agitation,Psychomotor

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects

RSV Infection

United States
Miguel Pampaloni
Molecular Insight Pharmaceuticals, Inc.; Jubilant DraxImage Inc.

Terminated

124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A Pilot Study

Neuroblastoma

United States
Jazz Pharmaceuticals
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer (SPRAY III)

Pain | Advanced Cancer

United States, Germany, United Kingdom, Mexico, Poland, Romania, Bulgaria, Czechia, Hungary, Puerto Rico
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS (OS440-3004)

Multiple Sclerosis | Spasticity, Muscle

Serbia, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Moldova, Republic of, Poland
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

Multiple Sclerosis | Spasticity

United States, Russian Federation, Ukraine
Tetraphase Pharmaceuticals, Inc.

Completed

Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections (IGNITE1)

Complicated Intra-abdominal Infections

United States, France, Ukraine, Argentina, Bulgaria, Romania, South Africa, Germany, Estonia, Russian Federation, Lithuania, Czechia, Latvia
Tetraphase Pharmaceuticals, Inc.

Completed

Study to Compare TP-434 and Ertapenem in Community-acquired Complicated Intra-abdominal Infections

Complicated Intra-abdominal Infection

United States, Latvia, Lithuania, Romania, India, Bulgaria
Tetraphase Pharmaceuticals, Inc.

Completed

Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections (IGNITE4)

Complicated Appendicitis | Complicated Intra-abdominal Infections

Ukraine, United States, Bulgaria, Romania, Estonia, Russian Federation, Lithuania, Hungary, Latvia, Georgia, Czechia
Tetraphase Pharmaceuticals, Inc.

Completed

A Thorough QT/QTc Study to Evaluate the Effects of an Intravenous Infusion of Eravacycline (TP-434) on Cardiac Repolarization

Normal Healthy Subjects
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity

Multiple Sclerosis | Spasticity

United States, Russian Federation, Ukraine
Tetraphase Pharmaceuticals, Inc.

Completed

A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects

Impaired Hepatic Function

United States
Tetraphase Pharmaceuticals, Inc.

Completed

A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With End Stage Renal Disease and Healthy Subjects

End Stage Renal Disease
Jazz Pharmaceuticals
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer

Pain | Advanced Cancer

United States, United Kingdom, Bulgaria, Belgium, Poland, Hungary, Romania, Czechia, Puerto Rico, Lithuania, Germany, Latvia
Jazz Pharmaceuticals
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer

Pain | Advanced Cancer

Israel, Italy, Taiwan, United Kingdom, Bulgaria, Hungary, India, Australia, Lithuania, Poland, Spain, Romania, Germany
Jazz Pharmaceuticals
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain

Pain | Advanced Cancer

Italy, United States, Taiwan, United Kingdom, Czechia, Bulgaria, Belgium, Latvia, Mexico, Lithuania, Poland, Romania, Hungary, Spain, Israel, Germany, Puerto Rico, Australia
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS (OS440-3005)

Multiple Sclerosis | Spasticity, Muscle

United States
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Withdrawn

To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS

Multiple Sclerosis | Sperm

United States
Tetraphase Pharmaceuticals, Inc.

Completed

Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections

cUTI

United States, Latvia, Poland, Czechia, Romania, Ukraine, Russian Federation, Georgia, Colombia, Bulgaria, Estonia, Greece, Hungary, Israel, Italy, Mexico, Moldova, Republic of, South Africa

Clinical Trials Sponsored by MingSight Pharmaceuticals, Inc

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kazakhstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations